Multicenter Study on Laparoscopic Total Gastrectomy for Advanced Gastric Cancer

Prior treatment

• Continuous systemic steroid therapy within 1 month (except for topical use)

Other illness

• Synchronous or metachronous (within 5 years) malignancies
• Body temperature ≥ 38℃ before surgery or infectious disease with a systemic therapy indicated
• Severe mental disease
• Severe respiratory disease, FEV1 \< 50% of predicted
• Unstable angina pectoris or history of myocardial infarction within 6 months
• History of cerebral infarction or cerebral hemorrhage within 6 months
• Gastric cancer complications (bleeding, perforation, obstruction) that requiring emergency surgery

Other

• Preoperative examinations indicate regional fusion of enlarged lymph nodes (max diameter ≥ 3.0cm) or enlargment of spleen hilus lymph nodes
• Women during pregnancy or breast-feeding
• Severe hepatic and renal dysfunction
• Patients are participating or have participated in another clinical trial (within 6 months)

• Aged 18-75 years
• Tumor located in the middle or upper third of the stomach, and curative resection is expected to be achievable by total gastrectomy with D2 lymphadenectomy (also apply to multiple primary cancers);
• Primary lesion is pathologically diagnosed as gastric adenocarcinoma, such as papillary adenocarcinoma, tubular adenocarcinoma, mucinous adenocarcinoma, poorly cohesive carcinoma (including signet ring cell carcinoma and other variants), and mixed adenocarcinoma;
• Clinical stage T2-4aN0-3M0 (According to AJCC-8th TNM staging system);
• Expected survival \> 6 months
• No invasion to Z-line;
• BMI (Body Mass Index) \< 30 kg/m2
• No history of upper abdominal surgery (except for laparoscopic cholecystectomy);
• No prior treatment of chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc
• Preoperative performance status (ECOG，Eastern Cooperative Oncology Group) of 0 or 1
• Preoperative ASA (American Society of Anesthesiologists) scoring: I-III
• Sufficient organ functions
• Written informed consent